Viral Vector, Non-Viral Vector and Gene Therapy Manufacturing Market is Expected to Grow at a CAGR of Approximately 15% through 2035, According to Roots Analysis



Root analysis

The increase in clinical research activity for genetically modified therapies has led to an increase in demand for vectors; providing lucrative opportunities for players with in-house and contract manufacturing capabilities of various types of vectors

London, Oct. 11, 2022 (GLOBE NEWSWIRE) — Root analysis announced the addition of “Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market, 2022-2035” report to its list of offers.

In recent years, cell and gene therapies have gained popularity due to their therapeutic potential. In fact, more than 20 genetically modified therapies have already been approved, which has led to an increase in demand for vectors, which have proven to be very effective in delivering genetic material to the targeted area. In order to meet the growing demand, several companies offer a diverse range of services for the manufacture of vectors and gene therapies.

To order this 685+ page report, which includes over 200 figures and over 285 tables, please visit

Key market information

More than 140 actors claim to manufacture viral and non-viral vectors
The market is currently dominated by the presence of various medium-sized industrial players (50%); of these, 57% of players are subcontractors, while 22% of players are in-house manufacturers.

Over time, several progress has been made for the development of vector technology platforms
The majority (37%) of available technologies are currently used in the manufacture of vectors, followed by those available for the manufacture of cell and gene therapies (16%). In addition, 53% of vector-based technologies are dedicated to the development and manufacture of adenoviral vectors.

More than 295 partnerships have been established between different stakeholders in the last decade
Nearly 55% of partnerships were reported after 2018, where a maximum of partnerships was recorded in 2022 (until may). Moreover, the maximum number of partnerships was related to manufacturing (23%), followed by license agreement (20%) and product development agreement (15%).

Nearly 120 expansion activities were recorded through 2022, growing at a CAGR of 10%
The majority of expansions in this area were related to the establishment of new facilities (39%), followed by the expansion of facilities (12%).

Installed vector manufacturing capacity is estimated at ~186,150 L
The majority (70%) of the total installed capacity is currently available for the clinical/commercial stage manufacturing of viral vectors. Additionally, players headquartered in North America (56%) have the highest installed capacity, globally.

Until 2035, the annual demand for vectors is expected to grow at an annualized rate of 11%
Currently, North America and Europe contribute over 70% of the demand for viral and non-viral vectors. By 2035, the demand, in terms of the number of clinical and commercial patients, demand for vectors, is expected to be around 400,000 patients.

The vector manufacturing market is expected to grow at a significant rate, during the period 2022-2035
The majority share of service revenue is expected to come from vector manufacturing projects focused on oncological disorders (51%). By 2035, Europe is expected to capture the majority (42%) of the market, followed by North America (30%) and Asia-Pacific (23%).

To request a sample copy/brochure of this report, please visit the link

Answers to key questions

  • Who are the main players (contract service providers and in-house manufacturers) involved in the development of vectors and gene therapies?

  • Which regions are the current manufacturing centers for vectors and gene therapies?

  • What types of technologies are currently being proposed/developed by the players involved in this field?

  • Which companies are likely to partner with contract manufacturing service providers of viral and non-viral vectors?

  • What partnership models are commonly adopted by players engaged in this industry?

  • What type of expansion initiatives are being undertaken by players in this field?

  • What are the emerging viral and non-viral vectors used by actors to manufacture genetically modified therapies?

  • What are the opportunities and threats for players engaged in this industry?

  • What is the current global demand for viral and non-viral vectors and gene therapies?

  • How is the current and future market opportunity likely to be distributed across key market segments?

By 2035, the financial opportunity in the manufacturing of viral vectors, non-viral vectors and gene therapies market has been analyzed in the following segments:

Scale of operation

Type of vectors

  • GO TO

  • Adenoviral

  • lentiviral

  • Retroviral

  • plasmid DNA

  • Other vectors


  • Genetical therapy

  • Cell therapy

  • Vaccines

Therapeutic area

  • Oncological disorders

  • Rare disorders

  • Neurological disorders

  • Sensory disorders

  • Metabolic disorders

  • Muscoskeletal disorders

  • Blood disorders

  • Immunological diseases

  • Others

Geographic regions

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • MENA

  • Rest of the world

The report also showcases contributions from prominent industry players that the predicted increase in demand for cell and gene therapies is the most significant driver for the growth of the vector supply market. The report includes detailed transcripts of discussions held with prominent industry representatives:

  • Menzo Havenga (CEO and President, Batavia Biosciences)

  • Nicole Faust (CEO and Scientific Director, CEVEC Pharmaceuticals)

  • Jeffrey Hung (former Chief Commercial Officer, Vigene Biosciences)

  • Cedric Szpirer (former Executive and Scientific Director, Delphi Genetics)

  • Olivier Boisteau, (Co-Founder / President, Clean Cells), Laurent Ciavatti (Former Business Development Manager, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells)

  • Alain Lamproye (Former President of the Biopharma Business Unit, Novasep)

  • Joost van den Berg (former director, Amsterdam BioTherapeutics Unit)

  • Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital)

  • Eduard Ayuso, DVM, PhD (Scientific Director, Translational Vector Core, University of Nantes)

  • Colin Lee Novick (Managing Director, CJ Partners)

  • Semyon Rubinchik (Scientific Director, ACGT)

  • Astrid Brammer (Senior Manager Business Development, Richter-Helm)

  • Marco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Former Marketing Manager, Plasmid Factory)

  • Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing)

  • Béatrice Araud (ATMP Key Account Manager, EFS-West Biotherapy)

  • Nicolas Grandchamp (R&D Manager, GEG Tech)

  • Géraldine Guérin-Peyrou (Marketing and Technical Support Director, Polypus Transfection)

  • Naiara Tejados, Head of Marketing and Technology Development, VIVEBiotech)

  • Jeffery Hung (Independent Consultant)

The research includes profiles of key players (listed below), with a brief company overview, financial performance (if applicable), information related to its manufacturing facilities, proprietary vector manufacturing technology and enlightened future prospects:

  • Advanced Bioscience Laboratories

  • Aldevron

  • Audentes Therapeutics

  • Innovative BioNTech manufacturing

  • BioReliance

  • Biovian

  • organic blue bird

  • Cell and gene therapy catapult

  • Celonic

  • Process Innovation Center

  • Cobra Organics

  • Emerging BioSolutions

  • EndVector

  • FUJIFILM Diosynth Biotechnologies

  • Kaneka Eurogentec

  • lonza

  • Meira GTx

  • MolMed

  • Novasep

  • Orchard therapy

  • Oxford BioMedica

  • Richter Helm

  • Sanofi

  • Therapeutic Spark

  • Thermo Fisher Scientific

  • uniQre

  • vibalogics

  • Vigene Biosciences

  • VIVEbiotech

  • Wuxi AppTech

For more details, please visit the link or send an email [email protected]

You might also be interested in the following titles:

  1. Global T Cell Therapies Market (CAR-T, TCR and TIL): Global industry trends and forecasts, 2022-2035

  2. Gene therapy market: Global industry trends and forecasts, 2022-2035

  3. Global Therapeutic Vaccines Market: Global industry trends and forecasts, 2022-2035

  4. CART-T Cell Therapies Intellectual Property Landscape: Industry Trends and Global Forecasts, 2022-2035

CONTACT: Gaurav Chaudhary [email protected] Roots Analysis A430, 4th Floor, Bestech Business Towers, Sector 66, Mohali, India [email protected] +1 (415) 800 3415 +44 (122) 391 1091 Web: LinkedIn: Twitter:

Source link


Comments are closed.